Behcet’s Syndrome and the Role of Off-Label Therapies in Improving Quality of Life
Behcet's Syndrome is a rare and chronic condition characterized by recurrent oral and genital ulcers, skin lesions, and eye inflammation. Currently, there is no cure for Behcet's Syndrome , and treatment is aimed at managing symptoms. However, recent developments in off-label therapies have dominated the Behcet's Syndrome Treatment marke t , according to a recent report by DelveInsight Business Research. The report highlights the rising prevalence of Behcet's Syndrome globally and the limited treatment options available. The lack of approved treatments has led to the widespread use of off-label therapies in managing symptoms. The most commonly used off-label therapies for Behcet's Syndrome include OTEZLA, REMICADE, and HUMIRA. Key developments in the Behcet’s syndrome treatment space so far OTEZLA , a phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA for the treatment of psoriasis and psoriatic arthritis in 2014. It has shown promising results in mana